CH365080A - Process for the production of new guanidines - Google Patents
Process for the production of new guanidinesInfo
- Publication number
- CH365080A CH365080A CH442961A CH442961A CH365080A CH 365080 A CH365080 A CH 365080A CH 442961 A CH442961 A CH 442961A CH 442961 A CH442961 A CH 442961A CH 365080 A CH365080 A CH 365080A
- Authority
- CH
- Switzerland
- Prior art keywords
- acid
- carbon atoms
- group
- guanido
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 15
- 150000002357 guanidines Chemical class 0.000 title description 6
- 238000004519 manufacturing process Methods 0.000 title description 2
- -1 1, 2-ethylene Chemical group 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 12
- 229930195733 hydrocarbon Natural products 0.000 claims description 9
- 239000004215 Carbon black (E152) Substances 0.000 claims description 8
- 239000007858 starting material Substances 0.000 claims description 8
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 150000001340 alkali metals Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 150000003459 sulfonic acid esters Chemical class 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 150000001339 alkali metal compounds Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229960004365 benzoic acid Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- ZQDSOUPBYJIPNM-UHFFFAOYSA-N 1-(2-chloroethyl)azepane;hydrochloride Chemical compound [Cl-].ClCC[NH+]1CCCCCC1 ZQDSOUPBYJIPNM-UHFFFAOYSA-N 0.000 description 2
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 2
- VMRYMOMQCYSPHS-UHFFFAOYSA-N 2-(azepan-1-yl)ethanol Chemical compound OCCN1CCCCCC1 VMRYMOMQCYSPHS-UHFFFAOYSA-N 0.000 description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- JECOSSASMXAXFV-UHFFFAOYSA-N chloroethane;hydrochloride Chemical compound Cl.CCCl JECOSSASMXAXFV-UHFFFAOYSA-N 0.000 description 2
- ZZTURJAZCMUWEP-UHFFFAOYSA-N diaminomethylideneazanium;hydrogen sulfate Chemical compound NC(N)=N.OS(O)(=O)=O ZZTURJAZCMUWEP-UHFFFAOYSA-N 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 229960003750 ethyl chloride Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229960004275 glycolic acid Drugs 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003388 sodium compounds Chemical class 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- BZCOSCNPHJNQBP-UPHRSURJSA-N (z)-2,3-dihydroxybut-2-enedioic acid Chemical compound OC(=O)C(\O)=C(\O)C(O)=O BZCOSCNPHJNQBP-UPHRSURJSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZTXXGFXIJMMZOP-UHFFFAOYSA-N 1-chloropropane;hydrochloride Chemical compound Cl.CCCCl ZTXXGFXIJMMZOP-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- LYNDKEYSEBKFIL-UHFFFAOYSA-N 2-(2-piperidin-1-ylethyl)guanidine;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.NC(=N)[NH2+]CC[NH+]1CCCCC1 LYNDKEYSEBKFIL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- HOXBVKNFGPBYHB-UHFFFAOYSA-N 2-[2-(azepan-1-yl)ethyl]guanidine;sulfuric acid Chemical compound OS(O)(=O)=O.NC(N)=NCCN1CCCCCC1 HOXBVKNFGPBYHB-UHFFFAOYSA-N 0.000 description 1
- JLWMMYZWEHHTFF-UHFFFAOYSA-N 2-[6-(3-carbamimidoylphenoxy)-4-[di(propan-2-yl)amino]-3,5-difluoropyridin-2-yl]oxy-5-(2-methylpropylcarbamoyl)benzoic acid Chemical compound OC(=O)C1=CC(C(=O)NCC(C)C)=CC=C1OC1=NC(OC=2C=C(C=CC=2)C(N)=N)=C(F)C(N(C(C)C)C(C)C)=C1F JLWMMYZWEHHTFF-UHFFFAOYSA-N 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- GURIWXOGJQPUIB-UHFFFAOYSA-N CC(C=C1)=CC=C1S(OCCCNC(N)=N)(=O)=O Chemical compound CC(C=C1)=CC=C1S(OCCCNC(N)=N)(=O)=O GURIWXOGJQPUIB-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010067598 Neurogenic hypertension Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- XENVCRGQTABGKY-ZHACJKMWSA-N chlorohydrin Chemical compound CC#CC#CC#CC#C\C=C\C(Cl)CO XENVCRGQTABGKY-ZHACJKMWSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000003944 halohydrins Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007530 organic bases Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 150000003112 potassium compounds Chemical class 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012609 strong anion exchange resin Substances 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Verfahren zur Herstellung neuer Guanidine
Gegenstand der vorliegenden Erfindung ist ein Verfahren zur Herstellung von neuen Guanidinen, nämlich der Alkylenimino-niederalkyl-guanidine der allgemeinen Formel I
EMI1.1
einen unsubstituierten oder durch Kohlenwasser stoffreste substituierten Alkyleniminoring mit 4-10 Ringkohlenstoffatomen bedeutet, A'eine Niederalkylengruppe darstellt, welche die Gruppe
EMI1.2
von der Guanidogruppe durch 2-7 Kohlenstoffatome trennt, und Rt Wasserstoff oder einen Kohlenwasserstoffrest bedeutet.
Die Alkyleniminogruppe dieser Verbindungen bildet einen 5-llgliedrigen Ring, vornehmlich aber mit 6-8 Ringkohlenstoffatomen einen 7-9gliedri- gen Ring, der unsubstituiert oder durch Kohlenwasserstoffreste, z. B. durch Niederalkyl, wie Methyl oder Äthyl, substituiert sein kann. Die Alkyleniminogruppe steht beispielsweise für Pyrrolidino, Piperidino, Hexa-, Hepta-, Octa-, Nona-oder Dekamethylenimino bzw. die entsprechenden, wie oben angegeben, ringsubstituierten Gruppen.
Der die Alkyleniminogruppe mit der Guanidogruppe verbindende Alkylenrest kann gerade oder verzweigt sein und enthält vorzugsweise nur 2-3 Kohlenstoffatome. Er steht somit speziell für 1, 2 Äthylen, 1, 2-, 2, 3- oder 1, 3-Propylen, aber beispielsweise auch für 1, 3-, 2, 3- oder 1, 4-Butylen, 1, 4- oder 1, 5-Pentylen, 1, 6-Hexylen oder 1, 7-Heptylen.
Die Guanidogruppe äst vorzugsweise unsubstituiert, jedoch kann sowohl die Amino-wie auch die Iminogruppe des Guanidorestes durch Kohlenwasserstoffreste, wie Alkylgruppen, z. B. Methyl-oder Äthylgruppen, substituiert sein.
Salze der neuen Verbindungen sind besonders solche mit therapeutisch verwendbaren Säuren, wie anorganischen Säuren, z. B. Halogenwasserstoffsäu- ren, beispielsweise Salzsäure oder Bromwasserstoffsäure, Perchlorsäure, Salpetersäure oder Thiocyan- sÏure, Schwefel-oder Phosphorsäuren, oder organischen Säuren, wie Ameisensäure, Essigsäure, Propionsäure, GlykolsÏure, Milchsäure, Brenztraubensäure, Oxalsäure, Malonsäure, BernsteinsÏure, MaleinsÏure, Fumarsäure, Äpfelsäure, WeinsÏure, Zitronensäure, AscorbinsÏure, HydroxymaleinsÏure, DihydroxymaleinsÏure, Benzoesäure, Phenylessigsäure, 4-Amino-benzoesäure, 4-Hydroxy-benzoe- säure, AnthranilsÏure, Zimtsäure, MandelsÏure, SalicylsÏure, 4-Amino-salicylsäure, 2-Phenoxy-ben zoesäure,
2-Acetoxy-benzoesäure, Methansulfonsäure, Äthansulfonsäure, HydroxyÏthansulfonsÏure, Benzolsulfonsäure, p-Toluol-sulfonsäure, Naphthalin-sulfonsäure oder Sulfanilsäure, oder Methionin, Tryptophan, Lysin oder Arginin. Dabei können Monooder Polysalze vorliegen.
Die neuen Guanidinderivate und ihre Salze zeigen blutdrucksenkende Wirksamkeit und können als blutdrucksenkende Mittel, besonders bei neurogener oder renaler Hypertension, verwendet werden. Sie sind, insbesondere die Alkylenimino-alkylguanidine, in denen die Alkyleniminogruppe 6-8 Kohlenstoff atome, ganz besonders 7 Kohlenstoffatome, aufweist und die keinen weiteren Substituenten oder nur eine Methylgruppe als Substituenten enthalten und deren Guanidogruppe unsubstituiert ist, wie auch ihre Salze, durch eine langandauernde Wirksamkeit ausgezeichnet. Eine ganz ausgezeichnete Wirksamkeit zeigen diejenigen der obengenannten Alkylenimino niederalkylguanidine, dn denen der Alkylrest 2-3 Kohlenstoffatome enthält, wie auch deren Salze.
Aus dieser Gruppe ragt in erster Linie noch das 2-Heptymethylenimino-äthyl-guanidin der Formel
EMI2.1
und dessen Säureadditionssalze, im besonderen dessen Sulfat, hervor.
Die neuen Verbindungen sollen als Heilmittel in Form von pharmazeutischen Präparaten verwendet werden, welche diese Verbindungen zusammen mit pharmazeutischen, organischen oder anorganischen, festen oder flüssigen Trägerstoffen, die für enterale, z. B. orale, oder parenterale Gabe geeignet sind, enthalten.
Das erfindungsgemässe Verfahren ist dadurch gekennzeichnet, dass man Verbindungen der Formel
EMI2.2
oder ihre Salze mit Verbindungen der Formel
EMI2.3
oder ihren Salzen umsetzt, wobei
EMI2.4
die oben angegebene Bedeutung haben, einer der Reste X und Y ein Wasserstoffatom und der andere einen reaktionsfähig veresterten HO-A'-Rest, in dem die veresterte Hydroxylgruppe von
EMI2.5
durch 2-7 Kohlenstoffatome getrennt wird, darstellt und X ausserdem ein Alkalimetallatom bedeutet. Wenn erwünscht, können erhaltene Verbindungen nach an sich bekannten Methoden acyliert und/ oder erhaltene Salze in die freien Verbindungen oder erhaltene freie Verbindungen in ihre Salze umgewandelt werden.
So kann man z. B. Alkylenimine oder Alkalimetallverbindungen davon mit einem reaktionsfähigen Ester eines Guanido-niederalkanols, worin die Guanidogruppe von der veresterten Hydroxylgruppe durch 2-7 Kohlenstoffatome getrennt wird, oder dessen Salzen umsetzen.
Reaktionsfähige Ester eines Guanidoniederalkanols sind beispielsweise solche von starken anorganischen Säuren, z. B. Mineralsäuren, wie Salzsäure, Brom-oder Jodwasserstoffsäure oder Schwefelsäure, oder von starken organischen Säuren, z. B. organischen Sulfonsäuren, wie p-Toluolsulfonsäure.
Die erfindungsgemässe Reaktion wird z. B. so durchgeführt, dass man das Alkylenimin oder eine Alkalimetall-, z. B. Natrium-oder Kaliumverbindung davon, mit dem reaktionsfähigen Guanido-niederalkanolester oder einem Salz davon, vorzugsweise in Gegenwart eines Verdünnungsmittels, umsetzt. Die genannten Ausgangsstoffe können auch unter den Reaktionsbedingungen gebildet werden, z. B. die Alkalimetallverbindung des Alkylenimins bei Umsetzung der Komponenten in flüssigem Ammoniak in Gegenwart von Alkalimetallen, wie Natrium oder Kalium, oder deren Carbonaten. Wird ein Salz des Guanidoniederalkanolesters verwendet, so kann die freie Base in einem alkalischen Reaktionsmedium in Freiheit gesetzt werden. Das Verdünnungsmittel wird somit im Hinblick auf die Reaktionskomponenten gewählt, bei Verwendung der freien Esterbase z.
B. ein Ather, wie p-Dioxan, oder ein Kohlenwasserstoff, wie Benzol oder Toluol, oder bei Verwendung eines Salzes ein Niederalkanol, wie Methanol oder Atha- nol. Die Reaktion kann unter Kühlung, vorzugsweise aber bei erhöhter Temperatur, falls erwünscht, in geschlossenem Gefäss, unter Druck oder in einer Inertgas-Atmosphäre durchgeführt werden.
Die Ausgangsstoffe können beispielsweise wie folgt erhalten werden : Alkalimetallverbindungen von Alkyleniminen werden z. B. durch Einwirkung von Alkalimetallen, wie Natrium oder Kalium, Alkalimetallhydriden oder-amiden, wie Natrium-oder Kaliumhydrid oder-amid, auf das Alkylenimin in Gegenwart eines inerten Verdünnungsmittels, z. B.
Toluol oder p-Dioxan, gebildet.
Die reaktionsfähigen Ester der Guanido-niederalkanole oder deren Salze können beispielsweise dadurch erhalten werden, dass man ein Guanidoniederalkanol mit einem Tbionylhalogenid, wie Thionylchlorid, z. B. in einem inerten Verdünnungsmittel, wie einem Kohlenwasserstoff, etwa Benzol oder Toluol, oder mit einem Sulfonylhalogenid, wie p Toluolsulfonylchlorid, in Pyridin umsetzt.
Bevorzugte Ausgangsstoffe sind solche der Formel
EMI2.6
worin A'einen 1, 2-Athylen-, 1, 2-, 2, 3- oder 1, 3 Propylenrest bedeutet und Z für ein Halogenatom, vornehmlich Chlor, oder einen Arylsulfonyloxyrest, vornehmlich den p-Toluol-sulfonyloxyrest, steht, z. B.
2-Guanido-äthylchlorid oder 3-p-Toluol-sulfonyloxypropyl-guanidin.
Anderseits kann man auch einen reaktionsfähigen Ester der obengenannten Art von einem Alkylenimino-niederalkanol oder einem Salz davon nach den vorerwähnten Methoden mit einem Guanidin oder dessen Salz umsetzen.
Die als Ausgangsstoffe verwendeten reaktiven Alkylenimino-niederalkanolester können nach an sich bekannten Methoden hergestellt werden, beispielsweise durch Umsetzung eines Alkylenimins mit einem Halogenhydrin, wie Athylenchlor-oder-bromhydrin, oder einem Epoxyd, wie Athylenoxyd, worauf erhaltene Alkylenimino-niederalkanole, wie oben er wähnt, in die reaktionsfähigen Ester, z. B. in die der Halogenwasserstoffsäuren, durch Behandlung mit einem Thionylhalogenid, übergeführt werden.
In den erhaltenen Alkylenimino-niederalkylguanidinen kann die Guanidogruppe acyliert werden, beispielsweise durch Behandlung der Guanidinverbindung mit einem reaktionsfähigen, funktionellen Derivat einer Carbonsäure, z. B. einem Halogenid, wie Chlorid, oder einem Anhydrid. Hierbei kann man die Reaktionskomponenten in Anwesenheit inerter Verdünnungsmittel, z. B. Kohlenwasserstoffen, wie Pentan, Hexan, Benzol, Toluol oder Xylol, oder tertiären organischen Basen, z. B. flüssigen Pyridinen, wie Pyridin oder Collidin, oder in Abwesenheit solcher umsetzen, z. B. durch Erhitzen mit dem Acylierungsmittel, z. B. Essigsäureanhydrid, allein, im offenen oder geschlossenen Gefäss unter Druck.
Alcylderivate der neuen Guanidinverbindungen sind solche von organischen Säuren, besonders Carbonsäuren, wie aliphatischen Carbonsäuren, z. B.
Alkancarbonsäuren, beispielsweise Ameisensäure, Essigsäure, Propionsäure oder Trimethylessigsäure, substituierten Alkancarbonsäuren, beispielsweise Tri fluoressigsäure, Hydroxyessigsäure oder Cyclopentylpropionsäure, oder Alkensäuren, beispielsweise Acrylsäure, oder aromatischen Carbonsäuren, z. B. monocyclischen, aromatischen Carbonsäuren, beispielsweise Benzoesäure, Hydroxybenzoesäure oder Amino-benzoesäure, oder bicyclischen, aromatischen Carbonsäuren, wie 1-Naphthoesäure oder 2-Naphthoesäure, oder heterocyclischen Carbonsäuren, z. B. monocyclischen, heterocyclischen Carbonsäuren, beispielsweise Nicotin-, Isonicotin-oder 2-Furancarbonsäure.
Die neuen Guanidinverbindungen werden entweder als freie Verbindungen oder dn Form ihrer Salze erhalten. Ein Salz kann in an sich bekannter Weise, beispielsweise durch Behandlung mit einem stark alkalischen Mittel, wie wässrigem Alkalimetallhydroxyd, z. B. Lithium-, Natrium-oder Kaliumhydroxyd, oder mit starken Anion-Austauscherharzen, wie quaternären Ammonium-Austauscherharzen, in die freie Verbindung übergeführt werden. Von den freien Basen können mit geeigneten, beispielsweise den eingangs erwähnten, anorganischen oder organischen Säuren therapeutisch anwendbare Additionssalze hergestellt werden. Die Umsetzung mit Säuren erfolgt vorzugsweise in geeigneten Verdün- nungsmitteln, z. B.
Niederalkanolen, wie Methanol, Athanol, n-Propanol oder i-Propanol, Athem, wie Diäthyläther oder Dioxan, Estern, wie Essigsäure- äthylester oder Mischungen dieser. Hierbei können basische, neutrale, saure oder gemischte Salze erhalten werden.
In den folgenden Beispielen sind die Temperaturen in Celsiusgraden angegeben.
Beispiel 1
Zu einer Mischung von 22, 6 g Heptamethylenimin und 75 cm3 Athanol fügt man 15, 8 g 2-Guanido äthylchlorid-hydrochlorid in äthanolischer Lösung, erhitzt das Reaktionsgemisch einige Stunden zum Sieden, kühlt ab, filtriert und engt das Filtrat unter vermindertem Druck ein. Den Rückstand löst man in Wasser, macht die Lösung mit verdünnter Natronlauge alkalisch und überführt die erhaltene Base durch Zusatz von Schwefelsäure in das 2-Hepta methylenimino-äthyl-guanidinsulfat, F. 276-281 (Zersetzung).
Das Heptamethylenimin kann auch in die Natriumverbindung übergeführt werden, beispielsweise durch Behandlung mit Natriumamid oder Natriumhydrid in Toluol. Die erhaltene Natriumverbindung lässt man mit 2-Guanido-äthylchlorid reagieren und löst das entstandene 2-Heptamethylen imino-äthyl-guanidin in Wasser. Die filtrierte Lösung lässt man durch eine Austauschersäule mit einem starken Anion- (sulfat)-austauscherharz, z. B. einem der in USP Nr. 2 591573 beschniebenen, laufen, engt die Lösung unter vermindertem Druck ein und kristallisiert das erhaltene 2-Heptamethylenimino-äthyl- guanidin-sulfat aus wässrigem Äthanol.
Anstelle von Heptamethylenimin können auch andere Alkylenimine eingesetzt werden, beispielsweise Penta-, Hexa-, Okta-oder Dekamethylenimin, die das entsprechende 2-Piperidino-äthyl-guanidin- sulfat vom F. 205-207 (Zersetzung), das 2-Hexa methylen-imino-äthyl-guanidin-sulfat vom F. 233 bis 236 (Zersetzung ; aus Äthanol-Diäthyläther), das 2-Oktamethylenimino-äthyl-guanidin-sulfat vomF. 272 bis 275 (Zersetzung ; aus Wasser) oder das 2-Deka methylenimino-äthyl-guanidin-sulfat vom F. 260 bis 273 (Zersetzung) ergeben.
Das Ausgangsmaterial kann wie folgt erhalten werden :
Zu einer Mischung von 10, 5 g 2-Guanido-äthanol- hydrochlorid und 500 cm3 Toluol fügt man unter Rühren 16, 9 g Thionylchlorid, lässt über Nacht stehen, erwärmt hierauf 30 Minuten, dekantiert das Toluol ab und dampft überschüssiges Thionylchlorid und Toluol ab. Das zurückbleibende 2-Guanido äthylchlorid-hydrochlorid kristallisiert man aus Athanol-Diäthyläther-Gemisch. Die freie Base erhält man durch Behandlung des Salzes mit einer stöchio- metrischen Menge Ammoniak in Gegenwart von Diäthyläther.
Ersetzt man bei obiger Reaktion das 2-Guanido äthanol durch das 3-Guanido-propanol, so erhält man das entsprechende 3-Guanido-propylchlorid-hydrochlorid. Setzt man dieses mit Heptamethylenimin, wie oben angegeben, um, so erhält man das 3-Heptamethylenimino-propyl-guanidin der Formel
NH (N-CHs-CHz-CHz-NH-C NH2 als Sulfat; es schmilzt nach dem Umkristallisieren aus Athanol-Diäthyläther und nachher aus Athanol Hexan bei 248-252 (Zersetzung).
Beispiel 2
Eine Mischung von 19, 8 g 2-Hexamethylenimino äthylchlorid-hydrochlonid, 21, 6 g Guanidinsulfat und Wasser alkalisiert man schwach mit Natronlauge, erhitzt am Wasserbad und setzt weitere Natronlauge zur Neutralisation der entstandenen Säure zu. Nach dem Abkühlen, Ansäuern mit Schwefelsäure und Einengen im Vakuum scheidet sich das 2-Hexa methylenimino-äthyl-guanidin-sulfat aus ; es kann durch Umkristallisieren aus wässrigem Athanol gereinigt werden ; F. 233-236 (Zersetzung).
In analoger Weise können auch die übrigen in Beispiel 1 genannten Verfahrensprodukte hergestellt werden.
Das Ausgangsprodukt erhält man wie folgt :
Eine Mischung von 26, 3 g Hexamethylenimin, 33, 2 g Äthylenbromhydrin, 200 cm3 Benzol und 15 g wasserfreiem Natriumcarbonat hält man über Nacht unter Rühren im Sieden, filtriert hierauf, engt unter vermindertem Druck ein und destilliert das erhaltene 2-Hexamethylenimino-äthanol ; Kip'13 98 bis 101 .
Zu einer Mischung von 5, 72 g 2-Hexamethylenimino-äthanol und 50 cm3 Benzol fügt man unter Rühren tropfenweise eine Lösung von 5, 12 g Thionylchlorid in 150 cm3 Benzol, erhitzt zum Sieden und rührt 2 Stunden weiter. Nach dem Abkühlen filtriert man den Niederschlag ab und kristallisiert das erhaltene 2-Hexamethylenimino-äthylchloridhydrochlorid aus Methanol-Diäthyläther, F. 212 bis 216 .
Bei Reaktion von Heptamethylenimin mit Athylenbromhydrin und Behandlung des gebildeten 2 Heptamethylenimino-äthanols mit Thionylchlorid erhält man das 2-Heptamethylenimino-äthylchlorid- hydrochlorid. Dieses kann nach der oben angegebenen Methode durch Behandlung mit Guanidnnsulfat in das 2-Heptamethylenimino-athyl-guanidin-sulfat übergeführt werden.
Process for the production of new guanidines
The present invention relates to a process for the preparation of new guanidines, namely the alkyleneimino-lower-alkyl-guanidines of the general formula I.
EMI1.1
denotes an unsubstituted or hydrocarbon radical substituted alkyleneimino ring with 4-10 ring carbon atoms, A 'represents a lower alkylene group which the group
EMI1.2
separates from the guanido group by 2-7 carbon atoms, and Rt is hydrogen or a hydrocarbon radical.
The alkyleneimino group of these compounds forms a 5-membered ring, but primarily a 7-9-membered ring with 6-8 ring carbon atoms, which is unsubstituted or by hydrocarbon radicals, e.g. B. by lower alkyl, such as methyl or ethyl, may be substituted. The alkylenimino group stands, for example, for pyrrolidino, piperidino, hexa-, hepta-, octa-, nona- or decamethyleneimino or the corresponding ring-substituted groups, as indicated above.
The alkylene radical connecting the alkyleneimino group to the guanido group can be straight or branched and preferably contains only 2-3 carbon atoms. It therefore stands specifically for 1, 2 ethylene, 1, 2-, 2, 3- or 1, 3-propylene, but also, for example, for 1, 3-, 2, 3- or 1, 4-butylene, 1, 4- or 1,5-pentylene, 1,6-hexylene or 1,7-heptylene.
The guanido group is preferably unsubstituted, but both the amino and the imino group of the guanido radical can be replaced by hydrocarbon radicals, such as alkyl groups, e.g. B. methyl or ethyl groups may be substituted.
Salts of the new compounds are especially those with therapeutically useful acids, such as inorganic acids, e.g. B. hydrohalic acids, for example hydrochloric acid or hydrobromic acid, perchloric acid, nitric acid or thiocyanoic acid, sulfuric or phosphoric acids, or organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, maleic acid , Malic acid, tartaric acid, citric acid, ascorbic acid, hydroxymaleic acid, dihydroxymaleic acid, benzoic acid, phenylacetic acid, 4-amino-benzoic acid, 4-hydroxy-benzoic acid, anthranilic acid, cinnamic acid, mandelic acid, salicylic acid, 2-saloxy-benzoic acid zoic acid,
2-Acetoxy-benzoic acid, methanesulfonic acid, ethanesulfonic acid, HydroxyÏthansulfonsÏure, benzenesulfonic acid, p-toluenesulfonic acid, naphthalene-sulfonic acid or sulfanilic acid, or methionine, tryptophan, lysine or arginine. Mono or poly salts can be present.
The new guanidine derivatives and their salts show antihypertensive activity and can be used as antihypertensive agents, especially in the case of neurogenic or renal hypertension. They are, in particular, the alkylenimino-alkylguanidines in which the alkylenimino group has 6-8 carbon atoms, especially 7 carbon atoms, and which contain no further substituents or only one methyl group as substituents and whose guanido group is unsubstituted, as is their salts, by a long-term effectiveness excellent. Those of the abovementioned alkylenimino-lower alkylguanidines in which the alkyl radical contains 2-3 carbon atoms, as well as their salts, are very effective.
From this group, 2-heptymethyleneimino-ethyl-guanidine of the formula stands out primarily
EMI2.1
and its acid addition salts, in particular its sulfate.
The new compounds are intended to be used as medicinal products in the form of pharmaceutical preparations which combine these compounds with pharmaceutical, organic or inorganic, solid or liquid carriers which are suitable for enteral, e.g. B. oral or parenteral administration are suitable.
The inventive method is characterized in that compounds of the formula
EMI2.2
or their salts with compounds of the formula
EMI2.3
or their salts converts, whereby
EMI2.4
have the meaning given above, one of the radicals X and Y is a hydrogen atom and the other is a reactive esterified HO-A 'radical in which the esterified hydroxyl group of
EMI2.5
is separated by 2-7 carbon atoms, and X also represents an alkali metal atom. If desired, the compounds obtained can be acylated and / or the salts obtained can be converted into the free compounds or the free compounds obtained into their salts by methods known per se.
So you can z. B. alkyleneimines or alkali metal compounds thereof with a reactive ester of a guanido-lower alkanol, in which the guanido group is separated from the esterified hydroxyl group by 2-7 carbon atoms, or react its salts.
Reactive esters of a guanidone lower alkanol are, for example, those of strong inorganic acids, e.g. B. mineral acids such as hydrochloric acid, hydrobromic or hydroiodic acid or sulfuric acid, or of strong organic acids, e.g. B. organic sulfonic acids such as p-toluenesulfonic acid.
The inventive reaction is z. B. carried out so that the alkyleneimine or an alkali metal, z. B. sodium or potassium compound thereof, with the reactive guanido-lower alkanol ester or a salt thereof, preferably in the presence of a diluent, reacted. The starting materials mentioned can also be formed under the reaction conditions, e.g. B. the alkali metal compound of alkylenimine when reacting the components in liquid ammonia in the presence of alkali metals such as sodium or potassium, or their carbonates. If a salt of the guanido lower alkanol ester is used, the free base can be set free in an alkaline reaction medium. The diluent is thus chosen with regard to the reaction components, when using the free ester base, for.
B. an ether such as p-dioxane, or a hydrocarbon such as benzene or toluene, or, if a salt is used, a lower alkanol such as methanol or ethanol. The reaction can be carried out with cooling, but preferably at elevated temperature, if desired, in a closed vessel, under pressure or in an inert gas atmosphere.
The starting materials can be obtained, for example, as follows: Alkali metal compounds of alkylenimines are z. B. by the action of alkali metals, such as sodium or potassium, alkali metal hydrides or amides, such as sodium or potassium hydride or amide, on the alkyleneimine in the presence of an inert diluent, e.g. B.
Toluene or p-dioxane.
The reactive esters of guanido-lower alkanols or their salts can be obtained, for example, by reacting a guanido-lower alkanol with a tbionyl halide such as thionyl chloride, e.g. B. in an inert diluent such as a hydrocarbon, such as benzene or toluene, or with a sulfonyl halide, such as p toluenesulfonyl chloride, in pyridine.
Preferred starting materials are those of the formula
EMI2.6
wherein A 'is a 1,2-ethylene, 1,2, 3 or 1,3 propylene radical and Z represents a halogen atom, primarily chlorine, or an arylsulfonyloxy radical, primarily the p-toluene-sulfonyloxy radical, e.g. . B.
2-guanido-ethyl chloride or 3-p-toluene-sulfonyloxypropyl-guanidine.
On the other hand, a reactive ester of the abovementioned type of an alkyleneimino-lower alkanol or a salt thereof can also be reacted with a guanidine or its salt by the methods mentioned above.
The reactive alkyleneimino-lower alkanol esters used as starting materials can be prepared by methods known per se, for example by reacting an alkyleneimine with a halohydrin, such as ethylene chloro- or bromohydrin, or an epoxide, such as ethylene oxide, whereupon the alkyleneimino-lower alkanols obtained, as mentioned above , into the reactive esters, e.g. B. in those of the hydrohalic acids, by treatment with a thionyl halide, converted.
In the resulting alkylenimino-lower alkylguanidines, the guanido group can be acylated, for example by treating the guanidine compound with a reactive, functional derivative of a carboxylic acid, e.g. B. a halide such as chloride, or an anhydride. Here you can the reaction components in the presence of inert diluents such. B. hydrocarbons such as pentane, hexane, benzene, toluene or xylene, or tertiary organic bases, e.g. B. liquid pyridines, such as pyridine or collidine, or implement in the absence of such, for. B. by heating with the acylating agent, e.g. B. acetic anhydride, alone, in an open or closed vessel under pressure.
Alcyl derivatives of the new guanidine compounds are those of organic acids, especially carboxylic acids, such as aliphatic carboxylic acids, e.g. B.
Alkanecarboxylic acids, for example formic acid, acetic acid, propionic acid or trimethyl acetic acid, substituted alkanecarboxylic acids, for example tri fluoroacetic acid, hydroxyacetic acid or cyclopentylpropionic acid, or alkenoic acids, for example acrylic acid, or aromatic carboxylic acids, e.g. B. monocyclic, aromatic carboxylic acids, such as benzoic acid, hydroxybenzoic acid or amino-benzoic acid, or bicyclic, aromatic carboxylic acids, such as 1-naphthoic acid or 2-naphthoic acid, or heterocyclic carboxylic acids, e.g. B. monocyclic, heterocyclic carboxylic acids, for example nicotinic, isonicotinic or 2-furancarboxylic acid.
The new guanidine compounds are obtained either as free compounds or in the form of their salts. A salt can in a manner known per se, for example by treatment with a strongly alkaline agent, such as aqueous alkali metal hydroxide, e.g. B. lithium, sodium or potassium hydroxide, or with strong anion exchange resins, such as quaternary ammonium exchange resins, can be converted into the free compound. Therapeutically applicable addition salts can be prepared from the free bases with suitable inorganic or organic acids, for example those mentioned at the beginning. The reaction with acids is preferably carried out in suitable diluents, e.g. B.
Lower alkanols such as methanol, ethanol, n-propanol or i-propanol, breaths such as diethyl ether or dioxane, esters such as ethyl acetate or mixtures of these. Basic, neutral, acidic or mixed salts can be obtained here.
In the following examples the temperatures are given in degrees Celsius.
example 1
15.8 g of 2-guanido ethyl chloride hydrochloride in ethanol solution are added to a mixture of 22.6 g of heptamethyleneimine and 75 cm3 of ethanol, the reaction mixture is heated to boiling for a few hours, cooled, filtered and the filtrate is concentrated under reduced pressure. The residue is dissolved in water, the solution is made alkaline with dilute sodium hydroxide solution and the base obtained is converted into 2-heptamethyleneimino-ethyl-guanidine sulfate by adding sulfuric acid, mp 276-281 (decomposition).
The heptamethyleneimine can also be converted into the sodium compound, for example by treatment with sodium amide or sodium hydride in toluene. The sodium compound obtained is allowed to react with 2-guanido-ethyl chloride and the 2-heptamethylene imino-ethyl-guanidine formed is dissolved in water. The filtered solution is passed through an exchange column with a strong anion (sulfate) exchange resin, e.g. B. one of the described in USP No. 2,591,573, the solution is concentrated under reduced pressure and the 2-heptamethyleneimino-ethyl-guanidine sulfate obtained crystallizes from aqueous ethanol.
Instead of heptamethyleneimine, other alkyleneimines can also be used, for example penta-, hexa-, octa- or decamethyleneimine, which contains the corresponding 2-piperidino-ethyl-guanidine sulfate of F. 205-207 (decomposition), the 2-hexa methylene imino-ethyl-guanidine sulfate from F. 233 to 236 (decomposition; from ethanol-diethyl ether), the 2-octamethyleneimino-ethyl-guanidine sulfate from F. 272 to 275 (decomposition; from water) or the 2-deca methylenimino-ethyl-guanidine sulfate with a temperature of 260 to 273 (decomposition).
The starting material can be obtained as follows:
16.9 g of thionyl chloride are added with stirring to a mixture of 10.5 g of 2-guanidoethanol hydrochloride and 500 cm3 of toluene, the mixture is left to stand overnight, then heated for 30 minutes, the toluene is decanted and excess thionyl chloride and toluene are evaporated . The remaining 2-guanido ethyl chloride hydrochloride is crystallized from an ethanol-diethyl ether mixture. The free base is obtained by treating the salt with a stoichiometric amount of ammonia in the presence of diethyl ether.
If, in the above reaction, the 2-guanido ethanol is replaced by the 3-guanido propanol, the corresponding 3-guanido propyl chloride hydrochloride is obtained. If this is reacted with heptamethyleneimine, as indicated above, 3-heptamethyleneimino-propyl-guanidine of the formula is obtained
NH (N-CHs-CHz-CHz-NH-C NH2 as sulfate; it melts after recrystallization from ethanol-diethyl ether and afterwards from ethanol-hexane at 248-252 (decomposition).
Example 2
A mixture of 19.8 g of 2-hexamethyleneimino ethyl chloride hydrochloride, 21.6 g of guanidine sulfate and water is made slightly alkaline with sodium hydroxide solution, heated on a water bath and further sodium hydroxide solution is added to neutralize the acid formed. After cooling, acidification with sulfuric acid and concentration in vacuo, the 2-hexa methylenimino-ethyl-guanidine sulfate separates out; it can be purified by recrystallization from aqueous ethanol; F. 233-236 (decomposition).
The other process products mentioned in Example 1 can also be prepared in an analogous manner.
The starting product is obtained as follows:
A mixture of 26.3 g of hexamethyleneimine, 33.2 g of ethylene bromohydrin, 200 cm3 of benzene and 15 g of anhydrous sodium carbonate is kept boiling overnight with stirring, then filtered, concentrated under reduced pressure and the 2-hexamethyleneiminoethanol obtained is distilled; Kip'13 98 to 101.
A solution of 5.12 g of thionyl chloride in 150 cm3 of benzene is added dropwise with stirring to a mixture of 5.72 g of 2-hexamethyleneiminoethanol and 50 cm3 of benzene, the mixture is heated to the boil and stirred for a further 2 hours. After cooling, the precipitate is filtered off and the 2-hexamethyleneimino-ethyl chloride hydrochloride obtained is crystallized from methanol-diethyl ether, mp 212 to 216.
When heptamethyleneimine is reacted with ethylene bromohydrin and the 2-heptamethyleneimino-ethanol formed is treated with thionyl chloride, 2-heptamethyleneimino-ethyl chloride hydrochloride is obtained. This can be converted into 2-heptamethyleneimino-ethyl-guanidine-sulfate by treatment with guanidine sulfate by the method given above.
Claims (1)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81921059A | 1959-06-10 | 1959-06-10 | |
| US819208A US3006913A (en) | 1959-06-10 | 1959-06-10 | Process for preparing (n,n-alkylene-imino)-lower alkyl-guanidines |
| US819209A US3055882A (en) | 1959-06-10 | 1959-06-10 | Reduction process for preparation of cyclic nitrogen compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH365080A true CH365080A (en) | 1962-10-31 |
Family
ID=27420131
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH442961A CH365080A (en) | 1959-06-10 | 1960-05-17 | Process for the production of new guanidines |
| CH442861A CH365079A (en) | 1959-06-10 | 1960-05-17 | Process for the production of new guanidines |
| CH562160A CH365081A (en) | 1959-06-10 | 1960-05-17 | Process for the production of new guanidines |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH442861A CH365079A (en) | 1959-06-10 | 1960-05-17 | Process for the production of new guanidines |
| CH562160A CH365081A (en) | 1959-06-10 | 1960-05-17 | Process for the production of new guanidines |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US3055882A (en) |
| CH (3) | CH365080A (en) |
| DE (1) | DE1146062B (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3236859A (en) * | 1966-02-22 | Guanidinoalkyl)-pyrrolidine derivatives | ||
| US3278542A (en) * | 1966-10-11 | |||
| GB952194A (en) * | 1960-12-23 | 1964-03-11 | Smith Kline French Lab | New guanidine derivatives and processes for preparing the same |
| US3185678A (en) * | 1961-08-04 | 1965-05-25 | Colgate Palmolive Co | Polymethyleniminoalkylamides |
| US3250794A (en) * | 1962-05-24 | 1966-05-10 | Robert R Mod | Fatty acid amides and esters thereof |
| SE321464B (en) * | 1962-08-23 | 1970-03-09 | Pharmacia Ab | |
| US3178433A (en) * | 1963-05-07 | 1965-04-13 | Ciba Geigy Corp | 3-amino-1-diazacycloalkyl-alkyl-guanidines |
| US3245997A (en) * | 1963-07-17 | 1966-04-12 | Searle & Co | 3-substituted 1-(1, 2, 3, 4-tetrahydro-2-isoquinolyl) alkyl-2-thioureas |
| US3317545A (en) * | 1963-08-21 | 1967-05-02 | Hoffmann La Roche | [2-(2, 6-dimethylpiperidino)ethyl]guanidines and intermediates |
| US3213098A (en) * | 1963-08-30 | 1965-10-19 | Upjohn Co | Amino substituted 3h-azepines and their preparation |
| US3252983A (en) * | 1963-10-16 | 1966-05-24 | Ciba Geigy Corp | Aralkyl compounds |
| US3364220A (en) * | 1963-11-13 | 1968-01-16 | Colgate Palmolive Co | Heterocyclicaminoalkylguanidines |
| US3239517A (en) * | 1964-10-12 | 1966-03-08 | Toldy Lajos | Phenothiazines having antihypertensive effect |
| FR2524887A1 (en) * | 1982-04-08 | 1983-10-14 | Bouchara Emile | NOVEL CYANOGUANIDINES, PROCESS FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME |
| US4978684A (en) * | 1987-11-13 | 1990-12-18 | The Rockefeller University | Method and agents for preventing staining of teeth |
| US5612332A (en) * | 1984-03-19 | 1997-03-18 | Alteon Inc. | Di- and triaminoguanidines, and methods of use |
| US5852009A (en) * | 1984-03-19 | 1998-12-22 | The Rockefeller University | Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon |
| US4983604A (en) * | 1987-11-13 | 1991-01-08 | The Rockefeller University | Inhibitors of nonenzymatic cross-linking |
| US5128122A (en) * | 1984-03-19 | 1992-07-07 | The Rockefeller University | Method and agents for preventing staining of teeth |
| US5468777A (en) * | 1984-03-19 | 1995-11-21 | The Rockefeller University | Method and agents for preventing and reversing the staining of teeth |
| US5140048A (en) * | 1984-03-19 | 1992-08-18 | The Rockefeller University | Inhibitors of nonenzymatic cross-linking |
| CZ284456B6 (en) * | 1992-02-15 | 1998-12-16 | Hoechst Aktiengesellschaft | Amino substituted benzylguanidines, process of their preparation and their use for preparing medicaments |
| US5212185A (en) * | 1992-08-14 | 1993-05-18 | G. D. Searle & Co. | Piperidinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension |
| US6197830B1 (en) | 1995-09-22 | 2001-03-06 | Bruce M. Frome | Method for achieving relief from sympathetically mediated pain |
| US5850840A (en) * | 1995-11-15 | 1998-12-22 | Alteon Inc. | Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts |
| US6110968A (en) * | 1995-12-26 | 2000-08-29 | The Picower Institute For Medical Research | Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts |
| US5877217A (en) * | 1995-12-26 | 1999-03-02 | Alteon Inc. | N-acylaminoalkyl-hydrazinecarboximidamides |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2852528A (en) * | 1958-09-16 | Heterocyclic compounds and method | ||
| DE874447C (en) * | 1944-08-22 | 1953-04-23 | Bruno Dr Boettcher | Process for the preparation of 5-thione-1,2-dithiols |
| CH349986A (en) * | 1954-03-03 | 1960-11-15 | Ciba Geigy | Process for the preparation of new basic substituted heterocycles |
| US2846382A (en) * | 1955-07-25 | 1958-08-05 | Ciba Pharmacentical Products I | New process for the preparation of amines |
| US2909523A (en) * | 1957-10-11 | 1959-10-20 | American Cyanamid Co | Substituted piperazines and method of preparing the same |
| US2957867A (en) * | 1958-06-23 | 1960-10-25 | Ciba Pharm Prod Inc | 1, 5-benzodiazepin-4-ones and process of producing same |
-
1959
- 1959-06-10 US US819209A patent/US3055882A/en not_active Expired - Lifetime
- 1959-06-10 US US819208A patent/US3006913A/en not_active Expired - Lifetime
-
1960
- 1960-05-17 CH CH442961A patent/CH365080A/en unknown
- 1960-05-17 CH CH442861A patent/CH365079A/en unknown
- 1960-05-17 CH CH562160A patent/CH365081A/en unknown
- 1960-06-01 DE DEC21576A patent/DE1146062B/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US3006913A (en) | 1961-10-31 |
| CH365081A (en) | 1962-10-31 |
| US3055882A (en) | 1962-09-25 |
| DE1146062B (en) | 1963-03-28 |
| CH365079A (en) | 1962-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH365080A (en) | Process for the production of new guanidines | |
| DE69913047T2 (en) | Process for the preparation of benzamide derivatives | |
| DE2458965B2 (en) | 3-Amino-indazole-N-carboxylic acid derivatives, process for their preparation and pharmaceuticals containing them | |
| DE69023928T2 (en) | DIAMINE COMPOUNDS AND DRUGS AGAINST CEREBRAL DISORDERS THAT CONTAIN THEM. | |
| DE2205815A1 (en) | N-(oxazolin-2-yl)-piperazine - with antitussive activity | |
| DE2345801A1 (en) | PYRIDINIUM SALT | |
| DE2511891A1 (en) | Anti-thrombotic dioxo-piperazine derivs - prepd. e.g. by cyclising N,N,N',N'-1,2-alkylene-diamine-tetraacetic acids with amines | |
| CH500983A (en) | Aminoisoquinoline derivs spasmolytic depressives | |
| CH449632A (en) | Process for the preparation of cyclic diazacycloalkane compounds | |
| DE2446254C2 (en) | 5-Substituted lower alkyl-1,3,4-thiadiazole-2-thiol compounds and processes for their preparation | |
| AT226732B (en) | Process for the production of new guanidine compounds | |
| DE2313256B2 (en) | 1 ^ -Benzisoxazol-3-acetamidoxime, its salts, process for its preparation and medicinal products containing these compounds | |
| AT226731B (en) | Process for the production of new guanidine compounds | |
| DE1793612C (en) | ||
| DE1493513C3 (en) | Sulphamylanthranilic acids, their therapeutically useful salts, processes for their production and pharmaceutical preparations containing them | |
| CH362079A (en) | Process for the production of new guanidines | |
| EP1252159A1 (en) | Method for producing heterocyclic compounds | |
| CH345893A (en) | Process for the production of new guanidines | |
| AT214936B (en) | Process for the preparation of new sulfonyl urethane amine salts | |
| AT266838B (en) | Process for the preparation of benzodiazepine derivatives | |
| DE2226063A1 (en) | 2,2-Disubstituted aminoalkanamides, their acid addition salts and processes for the preparation of these compounds | |
| CH398615A (en) | Process for the preparation of new quaternary piperazinium compounds | |
| AT205977B (en) | Process for the preparation of new, heterocyclic hydrazine derivatives | |
| CH634835A5 (en) | METHOD FOR PRODUCING NEW BENZODIAZEPINE DERIVATIVES. | |
| AT234685B (en) | Process for the preparation of new 3-phenyl-sydnonimines |